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Kidney-Yang Deficiency Syndrome (KYDS) is closely bound up with the immune response of immunocompromised 
patients. The study is to investigate whether retinoic acid-inducible gene-I (RIG-I)-mediated innate immune response 
participates in the development of KYDS in rats and evaluate the effect of Yougui pill (YGP) on the response in KYDS rats. 
KYDS rats were induced by intramuscular injection of hydrocortisone at the dose of 10 mg/kg/d for 15 days. YGP at 
concentrations of 2.43 g/kg/d and 4.86 g/kg/d were administered intragastrically to KYDS rats for 30 days. The results 
showed that the body weight, urinary 17-hydroxycorticosteroid (17-OHCS) level, spleen size and spleen index in KYDS rats 
were significantly decreased compared with healthy control rats, while YGP treatment reversed them towards normal level 
in a dose-dependent manner. Moreover, KYDS challenge not only strikingly increased the mRNA and protein expression 
levels of RIG-I, tripartite motif containing 25 (TRIM25), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) but also 
markedly enhanced the endogenous RIG-I polyubiquitination levels. Whereas, YGP treatment effectively reversed this 
tendency in a dose-dependent manner. In conclusion, these findings revealed that RIG-I-mediated innate immune response 
was closely bound up with the development of KYDS. And YGP exhibited certain anti-inflammatory effects on KYDS rats 
via inhibiting the RIG-I-mediated innate immune response.  
Keywords: Interleukin-6, Kidney-Yang deficiency syndrome, Retinoic acid-inducible gene-I, Tripartite motif containing 25, 
Tumor necrosis factor-α, Yougui pill 
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Kidney-Yang Deficiency Syndrome (KYDS) is a 
crucial concept of Traditional Chinese Medicine 
(TCM). The characteristic symptoms of KYDS 
patients mainly includes fatigue, thin stool, hearing 
impairment, soreness and weakness of waist and 
knees, looseness of teeth and cold feeling of whole 
body. Recently, with the development of animal 
experiments, KYDS has attracted the attention 
of many researchers1-4. Based on the fact that the 
unbalance of adrenal cortex hormones plays an 
essential role in the pathogenesis of KYDS, 
hydrocortisone, a kind of steroid hormone produced 
by adrenal gland cortex, has been used to establish 
animal models with KYDS. Virtually, hydrocortisone 
injection is the most popular method to make the 
model of KYDS5-7. Representative signs in the rats 
treated by hydrocortisone, including fatigue, 
weakness, reduced activity, weight loss, slowed 
reaction, sensation of chill and tendency to cluster, are 
similar to the symptoms of patients with KYDS. This 
method was going to be applied in this study. 
A recent research had demonstrated that the levels 
of proinflammatory cytokines and chemokines 
(interleukin-6 (IL-6), monocyte chemoattractant 
protein-1 (MCP-1) and tumor necrosis factor-α  
(TNF-α)) significantly increased in viral pneumonia 
in mice with KYDS, which highlighted the fact that 
KYDS was closely bound up with the immune 
response8. Moreover, many studies published in 
Chinese language also revealed the relationship 
between KYDS and immune response9,10. It is well 
known that host innate immune system plays a critical 
role in triggering the release of aforementioned 
proinflammatory cytokines and chemokines. And the 
pivotal event is the recognition of foreign substances 
by pattern recognition receptors, including Toll-like 
receptors (TLRs), retinoic acid-inducible gene-I 
(RIG-I)-like receptors (RLRs) and nucleotide-binding —————— *Corresponding author 
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oligomerization domain (NOD)-like receptors 
(NLRs)11. Especially, RIG-I signaling pathway has 
received extensive attention in recent years12-14.  
Normally, RIG-I is held in an inactive, closed 
conformation. The activation starts upon recognizing 
and binding to viral RNA by RIG-I helicase and 
regulatory domains. After that, the caspase activator 
recruitment domains (CARDs) of RIG-I is ubiquitinated 
by tripartite motif containing 25 (TRIM25)14. Activated 
CARDs of RIG-I then interact with mitochondrial 
antiviral signaling adaptor MAVS/VISA/IPS-1/Cardif, 
thus giving rise to the activation of interferon 
regulatory factor 3 (IRF3) and nuclear factor κB  
(NF-κB) and inducing the production of Type I 
interferon and proinflamatory cytokines15,16. It had 
been demonstrated that RIG-I signaling pathway  
and its subsequent production of proinflammatory 
cytokines (TNF-α and IL-6) were involved in aging-
related renal injury and inflammation in senescence-
accelerated mice17. However, despite the fact that IL-
6 and TNF-α were confirmed to be related to KYDS8-
10, no research has been done to investigate whether 
RIG-I-mediated innate immune response participates 
in the development of KYDS. More significantly, 
TLR4, the same pattern recognition receptor as RIG-I, 
has been confirmed to be related to KYDS in recent 
years18,19. Thus, trying to reveal the relationship 
between RIG-I and KYDS tends to be the purpose of 
this study. 
YGP, a classic TCM formula, was first recorded in 
Jingyue Quanshu in the year 1624. Based on the 
function of warming up kidney yang, it has been used 
to treat patients of KYDS for about 400 years. Many 
studies showed that YGP had notable curative 
effectiveness for KYDS1,18,20. Moreover, it had been 
proved to have anti-inflammatory effects on host 
immune response in the treatment of osteoarthritis and 
experimental autoimmune encephalomyelitis21-23. For 
these two reasons, this study was designed to 
elucidate its potential effects exerting on RIG-I-
mediated innate immune response in rats suffering 
from KYDS induced by hydrocortisone.  
 
Methodology 
 
Animals  
Fifty-six male Wistar rats (Grade SPF, 7 weeks, 
250±20 g) were purchased from Experimental Animal 
Center of Hubei Province (No. SCXK (E) 2015-0018, 
Wuhan, China). Rats were reared under standard 
laboratory conditions (temperature of 22±2℃, 
humidity of 55±10%, light/dark cycle of 12 h/12 h) 
with food and water freely available. All procedures 
involving laboratory animals were performed in 
accordance with the WHO International Guiding 
Principles for Biomedical Research Involving 
Animals and were approved by the local ethics 
committee of Hubei University of Chinese Medicine. 
 
Modeling and drug administration 
Following acclimatization for 1 week, rats (8 weeks) 
were randomly divided into 4 groups: (a) normal 
healthy control rats (N, n=14); (b) KYDS model rats 
(M, n=14); (c) KYDS model rats with YGP (Henan 
Wanxi Pharmaceutical Co., Ltd., Nanyang, China) at 
the low dose of 2.43 g/kg/d, which is equivalent to the 
clinical dosage (YL, n=14); (d) KYDS model rats 
with YGP at the high dose of 4.86 g/kg/d (YH, n=14). 
KYDS model rats were induced by intramuscular 
injection of hydrocortisone (Lijun Pharmaceutical 
Co., Ltd., Xi’an, China) at the dose of 10 mg/kg/d for 
15 days as previously described7, while the rats in the 
normal group were treated with equal volume of 
physiological saline. After KYDS models established 
successfully, the above-mentioned concentrations of 
YGP were administered intragastrically to KYDS 
model rats at the volume of 10 mL/kg/d for 30 days in 
YL and YH groups, whereas rats in N and M groups 
were treated with equal amount of distilled water. 
Rats were visually inspected for health conditions and 
weighed every three days for adjusting the dosage.  
 
Weight measurement and spleen isolation 
Body weight of all rats was measured and analyzed 
on the last day of 3 stages, including Stage I (8 weeks, 
after acclimatization of rats), Stage II (10 weeks,  
after establishment of KYDS models) and Stage III 
(14 weeks, after administration of YGP). Data 
were analyzed using SPSS 22.0 and values were 
presented as mean±standard deviation (͞x±s). After 
administration of YGP, rats were decapitated under 
ether anesthesia and spleens were rapidly separated 
for gross appearance observation, spleen index 
measurement and further analysis. Spleen index is 
equal to spleen weight divided by body weight.  
 
Enzyme-linked immunosorbent assay (ELISA) 
Urine was collected for 24 h from rats in each 
group and stored frozen at −20°C until ELISA assay 
on the last day of the 10th week and the last day of the 
14th week. Then urinary 17-hydroxycorticosteroid 
(17-OHCS) was measured using an ELISA kit 
(Jiancheng Bioengineering Institute, Nanjing, China) 
in accordance with the manufacturer's instructions. 
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Real-time quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) assay 
Total RNA was isolated from spleens using a 
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and 
contaminating genomic DNA was removed by DNase 
I digestion (Takara, Kyoto, Japan). 1 μg purified RNA 
was reverse-transcribed to cDNA using a M-MLV 
RTase cDNA Synthesis Kit (Takara, Kyoto, 
Japan). qRT-PCR amplification was performed using 
iQTM SYBR® Green Supermix (Bio-Rad, Hercules, 
California, USA) with iQTM5 Multicolor Real-Time 
PCR Detection System (Bio-Rad, Hercules, 
California, USA). A typical amplification system 
consisted of 2 μL cDNA, 0.5 μL of 5' and 3' primers 
and 12.5 μLi QTM SYBR® Green Supermix, and it 
was adjusted to a final volume of 25 μL with 
distilled water. The amplification parameters were set 
as follows: 1 cycle of predenaturation for 2 min at 
95℃ and 45 cycles of 5 s at 95℃, 15 s at 56℃ and  
30 s at 72℃. Fluorescence data were acquired at the 
72℃ step and during the melting-curve program. The 
primer sequences are shown in Table 1 and relative 
mRNA abundances are calculated according to 2-ΔΔCT 
method using β-Actin as the internal reference gene. 
 
Western blotting and immunoprecipitation analysis 
Spleen tissues were homogenized and treated with 
200 μL of RIPA lysis buffer (Bi Yuntian, Hefei, 
China) for 30 min on ice. After centrifugation at 
12000 g for 30 min at 4℃, the supernatants were 
collected and protein concentrations were quantitated 
via a bicinchoninic acid protein assay kit (Pierce, 
Rockford, Illinois, USA). For immunoblotting assay, 
equivalent amounts of protein samples were mixed 
with 4× laemmli buffer and boiled for 10 min and 
then separated by 10% SDS-polyacrylamide gel 
electrophoresis and transferred onto nitrocellulose 
membranes (GE Healthcare, Buckinghamshire, UK). 
The membranes were blocked with 5% nonfat milk 
and incubated with primary antibodies (anti-TRIM25 
(1:1000, Ab203210, Abcam, Cambridge, UK), anti-
TNFα (1:2000, Ab6671, Abcam, Cambridge, UK), 
anti-IL6 (1:2000, Ab9324, Abcam, Cambridge, UK), 
anti-β-Actin (1:5000, 66009-1-Ig, Protein Tech, 
Chicago, USA) over night at 4℃, followed by 
incubating with HRP-conjugated secondary antibodies 
(goat anti-mouse IgG, (1:5000, sc-2031, Santa Cruz 
Biotechnology Inc., Santa Cruz, California, USA) or 
goat anti-rabbit IgG (1:5000, sc-2030, Santa Cruz 
Biotechnology Inc., Santa Cruz, California, USA))  
for 1 h on a rocker. Results were visualized  
using a chemiluminescence detection kit (Bi Yuntian, 
Hefei, China). 
For immunoprecipitation assay, a fraction of 
whole cell lysate was used as the input and remain 
sample was incubated with 10 μL of 50% protein 
A/G-sepharose beads (Abmart, Shanghai, China) for 
10 min. After centrifugation at 12000 g for 5 min at 
4℃, the supernatants were collected and incubated 
with 2 μL anti-RIG-1 antibody (Ab45428, Abcam, 
Cambridge, UK) over night at 4℃, followed by 
incubating with 20 μL of 50% protein A/G-sepharose 
beads for 2 h at 4℃. After centrifugation at 1000 g for 
5 min at 4℃, the beads were collected and washed by 
RIPA lysis buffer (Bi Yuntian, Hefei, China), and 
followed by eluting with 25 μL 4× laemmli buffer 
(Bi Yuntian, Hefei, China) and boiling for 10 min. 
After centrifugation at 12000 g for 10 min, the 
supernatants were collected and analyzed by western 
blotting assay using anti-Ubiquitin (1:1000, Ab7780, 
Abcam, Cambridge, UK) as primary antibody, while 
the input was analyzed simultaneously using  
anti-RIG-I (1:2000) or anti-β-Actin (1:5000) as 
primary antibody. Remaining steps referred to 
western blotting assay. 
 
Immunolohistochemistry analysis  
Spleen tissues were fixed in 4% paraformaldehyde 
for 24 h at 4℃ and subsequently embedded with 
paraffin. The paraffin sections of spleen were 
deparaffinized with xylene and rehydrated through a 
graded alcohol series. Antigen retrieval was performed 
using 0.01 M citrate buffer (pH 9.0) at 95℃ for 15 min, 
followed by quenching with 3% hydrogen peroxide. 
After treatment in 10% normal goat serum 
(Gibco, Carlsbad, California, USA) at room temperature 
for 30 min, the sections were incubated with the primary 
antibodies (anti-RIG-I (1:200), anti-TRIM25 (1:200), 
anti-TNFα (1:100) and anti-IL6 (1:200)) over night at 
4℃. The sections were then rinsed in PBS and incubated 
with HRP-conjugated secondary antibodies and 
visualized with diaminobenzidine substrate (Maixin 
Biotechnology, Fuzhou, China). The slides were 
counterstained with hematoxylin and observed using a 
light microscope (BX53, Olympus, Tokyo, Japan). 
Table 1 — Primers used in real-time PCR 
Gene Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
β-Actin CGTTGACATCCGTAAAGAC TAGGAGCCAGGGCAGTA
RIG-I AAGCGTGCTCAGTGTTT ATTTCCGCAAATGTGAT 
TRIM25 CCGTCAAGGCTAAGGT TGTGGGCGGTATTGTA 
TNF-α CACCACGCTCTTCTGTC CTACGGGCTTGTCACTC 
IL-6 CTTCTTGGGACTGATGTT ACTGGTCTGTTGTGGGT 
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Results  
 
Effect on body weight of rats  
As illustrated in Table 2, body weight of all rats 
showed no significant differences in Stage I (ap>0.05). 
In Stage II, body weight of KYDS rats in group M, 
YL and YH decreased significantly compared  
with that of healthy control rats in group N 
(bp<0.001，cp=0.001). In Stage III, body weight of 
KYDS rats in group M reduced dramatically 
compared with that of healthy control rats in group  
N (dp<0.001), while YGP administration reversed 
them towards normal level in a dose-dependent 
manner in group YL and YH compared with that of 
KYDS rats in group M (ep<0.001).  
 
Effect on 17-OHCS in urine of rats 
ELISA results (Table 3) revealed that urinary  
17-OHCS of KYDS rats in group M, YL and YH 
decreased significantly compared with that of healthy 
control rats in group N (ap<0.001) in Stage II. In 
Stage Ⅲ, urinary 17-OHCS of KYDS rats in group  
M reduced dramatically compared with that of  
healthy control rats in group N (bp<0.001), while 
YGP administration reversed them towards normal 
level in a dose-dependent manner in group YL and 
YH compared with that of KYDS rats in group M 
(cp<0.01).  
 
Effect on spleens of rats  
As the maximal immune organ, spleen plays a 
crucial role in immune reaction. On the basis of this 
fact, rat spleens were analyzed in this study. 
As shown in (Fig. 1A) the size of spleens in KYDS 
rats was obviously shrinked compared with that of 
healthy control rats, while YGP treatment relieved the 
degree of this shrinkage in a dose-dependent manner. 
Moreover, in (Fig. 1B) the spleen index in KYDS rats 
(ap<0.01) was obviously reduced compared with that 
of healthy control rats, while the reduction was 
rescued by YGP treatment (bp<0.05). 
 
Table 3 — Effect on 17-OHCS in urine of rats (͞x ± s, nmol/L) 
 StageⅡ(10weeks) StageⅢ (14weeks) 
N 11.401±1.249 12.184±0.299 
M 6.196±0.225a 6.641±0.203b 
YL 5.976±0.27a 8.703±0.569c 
YH 6.357±0.212a 9.167±0.717c 
Stage ：Ⅱ 10 weeks, after establishment of KYDS models; 
Stage ：Ⅲ 14 weeks, after administration of YGP. N: the level of 
urinary 17-OHCS in normal healthy control rats; M: the level of 
urinary 17-OHCS in KYDS model rats induced by 
hydrocortisone; YL: the level of urinary 17-OHCS in KYDS 
model rats treated with YGP (2.43 g/kg/d); YH: the level 
of urinary 17-OHCS in KYDS model rats treated with YGP 
(4.86 g/kg/d). aP<0.001, compared with group N in Stage Ⅱ; 
bP< 0.001, compared with group N in Stage Ⅲ; cP<0.01, 
compared with group M in Stage Ⅲ. 
  
Fig. 1 — Effect on spleens of rats. (A): Morphological size of spleen. (B): Weight index of spleen. aP<0.01, compared with group N; 
bP<0.05, compared with group M. N: normal healthy control rats; M: KYDS model rats induced by hydrocortisone; YL: KYDS model 
rats treated with YGP (2.43 g/kg/d); YH: KYDS model rats treated with YGP (4.86 g/kg/d). 
Table 2 — Effect on body weight of rats (͞x ± s, g) 
 Stage Ⅰ (8 weeks) Stage Ⅱ (10 weeks) Stage Ⅲ (14 weeks) 
N 258.9±11.9 294.9±12.7 344.1±12.2 
M 263.2±13.9a 271.3±16.1b 290.8±15.5d 
YL 260.4±14.1a 268.5±15.8b 314.6±13.2e 
YH 264.7±14.4a 273.7±15.4c 331.1±11.8e 
Stage Ⅰ: 8 weeks, after acclimatization of rats; Stage Ⅱ: 10 weeks,
after establishment of KYDS models; Stage Ⅲ: 14 weeks, after
administration of YGP. N: the weight of normal healthy control 
rats; M: the weight of KYDS model rats induced by
hydrocortisone; YL: the weight of KYDS model rats treated with
YGP (2.43 g/kg/d); YH: the weight of KYDS model rats treated
with YGP (4.86 g/kg/d). aP>0.05, compared with group N in
Stage Ⅰ; bP<0.001， cP = 0.001, compared with group N in
Stage Ⅱ; dP<0.001, compared with group N in Stage Ⅲ; eP<0.001, 
compared with group M in Stage Ⅲ. 
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Effect on expression, ubiquitination and distribution of RIG-I 
in spleens of rats 
RIG-I, activated by TRIM25-mediated ubiquitination, 
plays a crucial role in host innate immune system. 
A series of measures were applied to explore the 
expression, ubiquitination and distribution of RIG-I in 
rat spleens to study the effect of KYDS modeling and 
subsequent administration of YGP in rats. 
Relative expression levels of RIG-I mRNA were 
determined using qRT-PCR assay. As (Fig. 2A) 
presents, the mRNA expression level dramatically 
increased in the spleens of KYDS rats (ap<0.001) 
compared with that of healthy control rats. Following 
the administration of YGP, the remarkable increase 
was effectively reversed, tending to close to the 
normal level in a dose-dependent manner (bp<0.001), 
compared with that in KYDS rats.  
Furthermore, given that ubiquitination of  
N-terminal CARDs is vital for the activation of  
RIG-I to trigger subsequent immune responses, the 
assessment of endogenous RIG-I polyubiquitination 
level was conducted by combining western blotting 
with immunoprecipitation analysis. The results 
demonstrated that endogenous RIG-I polyubiquiti-
nation underwent markedly enhanced in the spleens of 
KYDS rats, compared with that of healthy control 
rats. Undoubtedly, this tendency was potently 
suppressed by the administration of YGP in a dose-
dependent manner (Fig. 2B).  
Finally, Results of immunohistochemistry staining 
(Fig. 2C & Fig. 2D) confirmed that the distribution of 
RIG-I protein exhibited the same tendency. In normal 
health rats, the spleen section showed scattered 
granular signals of brown staining and low percentage 
of positive cells. KYDS challenge caused 
significantly advanced staining intensity, giving rise 
to concentrated signal distribution of dark brown 
staining and higher percentage of positive cells 
(ap<0.001). The additional administration of YGP 
effectively diminished the density of signals, 
reversing to the scattered distribution, with the 
staining intensity still stronger than the normal level. 
Also, the YGP treatment can lower the percentage of 
positive cells compared to KYDS challenge (bp<0.01, 
cp<0.001). 
 
Effect on expression and distribution of TRIM25 in spleens  
of rats 
TRIM25, an E3 ubiquitin ligase, is necessary for 
the activation of RIG-I through attachment of 
polyubiquitin chains, which plays a vital role in 
triggering innate immune response. Given that 
  
Fig. 2 — Effect on expression, ubiquitination and distribution of RIG-I in spleens of rats 
(A): Relative mRNA levels of RIG-I. The mRNA levels of 14 rats in each group were determined using qRT-PCR assay by normalizing 
to β-Actin. Data indicate the mean ± standard deviation of three independent experiments. aP<0.001, compared with group N; bP<0.001, 
compared with group M. (B): Endogenous polyubiquitination of RIG-I. Endogenous polyubiquitination of RIG-I was analyzed by 
immunoprecipitation with anti-RIG-I and subsequent immunoblot with anti-Ubiquitin using WCL as the input and anti-β-Actin as the 
control. The protein sample of 7 rats in each group was analyzed as a whole. (C): Distribution of RIG-I. Immunohistochemistry staining 
was performed using anti-RIG-I (bar=20 μm). (D): Percentage of positive cells derived from the immunohistochemistry staining result.
aP<0.001, compared with group N; bP<0.01, cP<0.001, compared with group M. N: normal healthy control rats; M: KYDS model 
rats induced by hydrocortisone; YL: KYDS model rats treated with YGP (2.43 g/kg/d); YH: KYDS model rats treated with YGP
(4.86 g/kg/d). RIG-I: retinoic acid-inducible gene-I; Ub: Ubiquitin; WCL: whole cell lysate.
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endogenous polyubiquitination of RIG-I was affected 
by KYDS challenge and additional YGP 
administration, the effect on TRIM25 was explored. 
qRT-PCR assay results (Fig. 3A) demonstrated that 
the mRNA expression of TRIM25 also increased in 
the spleens of KYDS rats (ap<0.001), compared with 
that of healthy control rats, but the trend of increase 
was lower than that of RIG-I. Additional 
administration of YGP also reversed the increase 
caused by KYDS challenge in a dose-dependent 
manner (bp=0.001, cp<0.001), compared with that  
of KYDS rats.  
Moreover, western blotting analysis (Fig. 3B) 
revealed that the expression level of TRIM25 protein 
was enhanced in the spleens of KYDS rats (ap<0.001) 
compared with that in normal healthy control rats. 
However, this enhancement was suppressed by the 
subsequent administration of YGP in a dose-
dependent manner (bp<0.01, cp<0.001). 
Finally, immunohistochemistry staining results 
(Fig. 3C & Fig. 3D) confirmed that the distribution of 
TRIM25 protein exhibited very few scattered 
dot signals of weak light brown staining in the spleen 
section of normal health rat and low percentage of 
positive cells, whereas the staining intensity 
significantly enhanced in the spleen section of  
KYDS rat, resulting in dramatically higher  
percentage of positive cells (ap<0.001). Besides, the 
additional administration of YGP gave rise to the 
moderate level of staining signals, which is stronger 
than the N group but weaker than the M group. Also, 
the YGP treatment can efficiently lower the 
percentage of positive cells compared to KYDS 
challenge (bp<0.001). 
 
Effect on expression and distribution of TNF-α and IL-6 in 
spleens of rats 
After ubiquitination and activation by TRIM25, 
RIG-I is involved in the activation of interferon 
regulatory factor 3 and nuclear factor κB and the 
induction of type I interferon and proinflamatory 
cytokines. To further determine whether RIG-I is 
functional to respond to KYDS challenge and 
additional YGP administration, the expression and 
distribution of the critical downstream proin-
flammatory mediators (TNF-α and IL-6) were 
investigated. 
qRT-PCR assay results (Fig. 4A) demonstrated that 
the mRNA expression levels of TNF-α and IL-6 were 
sharply increased in the spleens of KYDS rats, 
compared with that of healthy control rats (ap<0.001, 
  
Fig. 3 — Effect on expression and distribution of TRIM25 in spleens of rats 
(A): Relative mRNA levels of TRIM25. The mRNA levels of 14 rats in each group were determined using qRT-PCR assay by normalizing to β-
Actin. Data indicate the mean ± standard deviation of three independent experiments. ap<0.001, compared with group N; bP=0.001, cP<0.001, 
compared with group M. (B): Protein levels of TRIM25. Protein levels were determined by western blotting with anti-TRIM25, using anti-β-
Actin as the control. The protein sample of 7 rats in each group was analyzed as a whole. Data of relative protein expression level indicate the 
mean ± standard deviation of three independent experiments. ap<0.001, compared with group N; bp<0.01, cp<0.001, compared with group M. (C): 
Distribution of TRIM25. Immunohistochemistry staining was performed using anti-TRIM25 (bar=20 μm). (D): Percentage of positive cells 
derived from the immunohistochemistry staining. ap<0.001, compared with group N; bp<0.001, compared with group M. N: normal healthy 
control rats; M: KYDS model rats induced by hydrocortisone; YL: KYDS model rats treated with YGP (2.43 g/kg/d); YH: KYDS model rats
treated with YGP (4.86 g/kg/d). TRIM25: tripartite motif containing 25.  
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cp<0.001), among which the increasing trend of  
IL-6 was more significant. Subsequently, the two  
up-regulated expression levels induced by KYDS 
challenge were efficiently alleviated by YGP 
treatment in a dose-dependent manner (bp<0.001, 
dp<0.001).  
Also, according to the analysis of western blot  
(Fig. 4B), the protein expression levels of TNF-α and 
IL-6 were evidently enhanced in the spleens of KYDS 
rats (ap<0.001, cp<0.001), compared with that 
of healthy control rats, whereas both the elevated 
expression levels were suppressed by YGP treatment 
in a dose-dependent manner (bp<0.001, dp<0.001).  
Finally, the results of immunohistochemistry 
staining (Fig. 4C & Fig. 4D) provided more intuitive 
evidence for the variation of TNF-α and IL-6. In 
normal condition, the spleen sections exhibited very 
weak signals of these two factors and low percentage 
of positive cells. Responding to KYDS challenge, the 
staining intensity was dramatically enhanced, with the 
distribution of TNF-α showed concentrated dot 
signals, whereas the distribution of IL-6 exhibited 
stretched strip-like signals. Also, the percentage of 
positive cells was obviously increased (ap<0.001, 
cp<0.001) under the pressure of KYDS challenge. 
When it comes to YGP treatment, these two enhanced 
signal distribution patterns were effectively suppressed, 
leading to lower percentage of positive cells 
compared to KYDS challenge (bp<0.001, dp<0.05, 
ep<0.001). 
 
Discussion  
In China, TCMs are widely used to prevent and 
treat a great number of diseases. When it comes to 
  
Fig. 4 — Effect on expression and distribution of TNF-α and IL-6 in spleens of rats 
(A): Relative mRNA levels of TNF-α and IL-6. The mRNA levels of 14 rats in each group were determined using qRT-PCR assay by 
normalizing to β-Actin. Data indicate the mean ± standard deviation of three independent experiments. ap<0.001, cp<0.001, compared 
with group N; bp<0.001, dp<0.001, compared with group M. (B): Protein levels of TNF-α and IL-6. Protein levels were determined by 
western blotting with anti-TNF-α and anti-IL-6, using anti-β-Actin as the control. The protein sample of 7 rats in each group was
analyzed as a whole. Data of relative protein expression level indicate the mean ± standard deviation of three independent experiments. 
ap<0.001, cp<0.001, compared with group N; bp<0.001, dp<0.001, compared with group M. (C): Distribution of TNF-α and IL-6. 
Immunohistochemistry staining was performed using anti-TNF-α and anti-IL-6 (bar=20 μm). D: Percentage of positive cells derived from 
the immunohistochemistry staining.ap<0.001, cp<0.001, compared with group N; bp<0.001, dp<0.05, ep<0.001, compared with group M. 
N: normal healthy control rats; M: KYDS model rats induced by hydrocortisone; YL: KYDS model rats treated with YGP (2.43 g/kg/d); 
YH: KYDS model rats treated with YGP (4.86 g/kg/d). TNF-α: tumor necrosis factor-α; IL-6: interleukin-6. 
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immunological diseases, TCMs have performed well 
in clinical practices and played dual roles in the 
regulation of immune responses. It has been 
demonstrated that TCMs can not only exert 
stimulatory effects on immune cells, immune organs, 
cytokine production and tumorigenesis, but also  
exert inhibitory effects on inflammation, allergy, 
autoimmune disease and graft rejection24-26. Although 
many clinical practices have highlighted the 
immunomodulatory effects of TCMs, there is little 
experience and limited data to support this claim in 
animal models. As the establishment of KYDS model, 
it tends to be a good choice for revealing the role of 
TCMs in immune regulation. KYDS is applied in 
TCM to describe a state in which the patients show 
characteristic symptoms mainly including fatigue, 
thin stool, hearing impairment, soreness and weakness 
of waist and knees, looseness of teeth and cold feeling 
of whole body. Also, it is prevalent in immune-
compromised patients and is closely bound up with 
the immune response8-10. Thus, our findings were in 
keeping with these previous studies and adopted 
hydrocortisone-treated rats as animal models to 
explore the immunomodulatory effects in the 
development of KYDS.  
The essence of kidney in Chinese medicine 
includes the functions of hypothalamus-pituitary-
adrenal cortex, thyroid and gonad. At present, the 
animal model of KYDS is mainly judged by whether 
it has the similar clinical manifestations to human 
KYDS and whether its thyroid, adrenal, reproductive 
capacity and immune level are disordered27. In this 
experiment, the pregnant rats in the model group had 
the symptoms of fatigue, weakness, reduced activity, 
weight loss, slowed reaction, sensation of chill and 
tendency to cluster. Moreover, the urinary 17-OHCS 
in the model rats is significantly decreased than that in 
the normal group. All these symptoms are similar to 
the symptoms of patients with KYDS and are 
consistent with previous studies, which give rise to 
the fact that our experimental model of kidney 
deficiency is successful.  
YGP, a classic TCM formula, had been proved to 
have notable curative effectiveness for KYDS1,18,20. 
Undoubtedly, it was proved in this study. After 
hydrocortisone treatment, KYDS rats showed weight 
loss, fatigue, sluggish and tendency to cluster. YGP 
administration could make these manifestations 
improved. Moreover, YGP treatment effectively 
reversed the weight loss and spleen shrinkage in 
KYDS rats in a dose-dependent manner. Furthermore, 
YGP had been proved to have anti-inflammatory 
effect to regulate the host immune responses in 
previous study21-23. Thus, this study was designed to 
elucidate its potential effects exerting on 
immune responses in KYDS rats. 
It has been demonstrated that levels of 
proinflammatory mediators (TNF-α and IL-6) 
significantly increased in animal models with  
KYDS8-10. And it has been well known that RIG-I 
signaling pathway plays a critical role in triggering 
the release of proinflammatory mediators (TNF-α and 
IL-6)15-17. Based on these two facts, this study was 
aimed at investigating whether the RIG-I-mediated 
innate immune response participates in the 
development of KYDS in rats and evaluating the 
effect of YGP on RIG-I-mediated innate immune 
response in KYDS rats. 
The results collectively showed that KYDS 
challenge not only strikingly increased the mRNA and 
protein expression levels of RIG-I but also markedly 
enhanced the endogenous RIG-I polyubiquitination 
levels in rat spleens, which could trigger host innate 
immune system. Whereas, subsequent YGP treatment 
effectively reversed this tendency in a dose-dependent 
manner in the spleens of KYDS rats, suggesting that 
the administration of YGP could relieve the RIG-I-
mediated innate immune response induced by KYDS.  
Normally, RIG-I is held in an inactive, closed 
conformation. And TRIM25 is necessary for the 
activation of RIG-I through attachment of 
polyubiquitin chains, which plays a vital role in 
triggering the RIG-I-mediated innate immune 
response. Consistent with the effect on RIG-I, KYDS 
challenge also enhanced the mRNA and protein 
expression levels of its activator (TRIM25), whereas, 
subsequent YGP treatment effectively reversed this 
tendency in a dose-dependent manner in the spleens 
of KYDS rats. These results indicated that TRIM25, 
as a necessary factor for activation of RIG-I, might 
play an important role in the immune stress response 
induced by KYDS and YGP treatment.  
After ubiquitination and activation by TRIM25, 
RIG-I is involved in the activation of IRF3 and  
NF-κB and the induction of Type I interferon and 
proinflamatory cytokines. In this study, KYDS 
challenge obviously increased the mRNA and protein 
expression levels of the critical downstream 
proinflammatory mediators (TNF-α and IL-6) in rat 
spleens, suggesting that the RIG-I signaling pathway 
is functional to respond to the challenge via triggering 
the release of the aforementioned two factors. 
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Especially, the increase in the expression of these  
two factors was consistent with previous results 
revealed in animal models with KYDS8-10. However, 
additional YGP treatment effectively reversed the 
increase of these two factors in a dose-dependent 
manner in the spleens of KYDS rats, giving rise to a 
strong inference that the RIG-I-mediated innate 
immune response in KYDS rats was efficiently eased 
by YGP administration. 
 
Conclusion  
The evidence presented in this study has revealed, 
for the first time, the levels of RIG-I, its activator 
(TRIM25) and its subsequent production (TNF-α and 
IL-6) all increased in the spleens of KYDS rats, 
demonstrating that RIG-I-mediated innate immune 
response was closely bound up with the development 
of KYDS. YGP at concentrations of 2.43 g/kg/d and 
4.86 g/kg/d exhibited certain therapeutic effects  
on KYDS rats, via decreasing the levels of 
aforementioned factors in a dose-dependent manner in 
the spleens of KYDS rats. The fact that YGP can 
effectively regulate the host immune response in 
KYDS rats proposes a promising future for TCMs in 
immunomodulatory therapies. 
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